Novartis Gene Therapies - Company Profile
Powered by
All the data and insights you need on Novartis Gene Therapies in one report.
$295
- Save hours of research time and resources with
our up-to-date Novartis Gene Therapies Strategy Report
- Understand Novartis Gene Therapies position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Novartis Gene Therapies’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
---|---|---|---|---|
01 Jul 2021 | AGC Biologics Acquires Longmont, Colorado Facility from Novartis Gene Therapies | Asset Transaction |
AGC Biologics Inc
|
Novartis Gene Therapies |
18 May 2020 | Avexis Enters Manufacturing and Packaging Agreement with Almac for Zolgensma | Contract Service Agreement |
Novartis Gene Therapies
|
Almac Group Ltd |
16 Jul 2019 | Catalent Announces Agreement with AveXis for Additional Production of Zolgensma | Contract Service Agreement |
Novartis Gene Therapies
|
Catalent Inc |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer